A 2 YEAR OLD WITH REFRACTORY AML CBFA2T3-GLIS2 ONCOGENIC FUSION: TRIAL WITH A NOVEL TARGET THERAPY (ASPHO 2024) - Mar 13, 2024 - Abstract #742; Pres time: Apr 5, 2024; 12:30 PM - 02:30 PM; "Due to persistent refractory disease, salvage therapy ensued with Venetoclax, Azacitidine, and Gemtuzumab Ozogamicin. Despite 7 cycles of STRO002 with Plerixafor on cycles 4-6; bone marrow evaluation showed refractory disease with FOLR1 expression on a minor subset... In the context of high-risk AML this case explores the utilization of FOLR1-directed antibody therapy in a patient with a CBFA2T3-GLIS2 mutation. Further advacement in target therapies is needed to potentially improve outcomes for pediatric patients with high risk AML."
Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Pediatrics • Transplantation • CBFA2T3 • FOLR1 • GLIS2
|
|
Maria Godoy; Almaha Alshehri; silvia Escudero; Ossama Maher
|